Patents Assigned to Canget BioTekpharma, LLC
  • Patent number: 12187735
    Abstract: Described herein, are the chemical synthesis, matter of compositions, formulation, function, methods and uses of the FL118 platform Positions 7 and/or 9-derived analogues for treating cancer or other human diseases. Compounds derived from chemical modifications of the FL118 platform are employed alone or in combination with other anti-cancer agents to preclude, eliminate or reverse cancer phenotypes. This invention intends to realize unique personalized cancer treatment (personalized precision medicine) through application of a series of structural relevant individual FL118 platform-derived analogues, which target multiple cellular human disease-relevant proteins and their signaling pathways.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: January 7, 2025
    Assignee: Canget BioTekpharma LLC
    Inventors: Xiang Ling, Qingyong Li, Fengzhi Li
  • Publication number: 20180170944
    Abstract: Described herein, are FL118 core structure platform compounds, matter of compositions, formulation, methods and uses for treating cancer or other human diseases. Chemical modifications of the FL118 structure are employed alone or in combination with other anti-cancer agents to preclude or reverse refractory cancer phenotypes and for unique personalized cancer treatment (personalized medicine or as Obama called precision medicine) through application of a series of structural relevant individual FL118 platform-derived analogues.
    Type: Application
    Filed: March 24, 2015
    Publication date: June 21, 2018
    Applicant: Canget BioTekpharma, LLC
    Inventors: Fengzhi LI, Xiang LING